newsfilter
← Latest News
Business Wire·

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with 214 patients with topline data readout on track